Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic

NTCD-M3 is staying developed to beat Clostridioides difficile bacterial infections (CDI) in the gut () explained it is teaming up with the US Division of Veterans Affairs to find “new attributes” for its next-era treatment. The evaluation of NTCD-M3, which is staying developed to beat Clostridioides difficile bacterial infections () […]